AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical property and has achieved significant results,” reads a recent article. AnPac Bio has one of the largest sample libraries in the world, with more than 220,000 samples tested. Its proprietary cancer differentiation analysis (“CDA”) technology has shown to be advantageous over traditional detection methods, allowing it to outperform in the early detection market. “As a pioneer in the application of biophysics to cancer prevention and treatment, AnPac Bio continues to report new ideas and cutting-edge technology to the public, sharing the latest clinical study and trial results, and continuing to promote collaborations between industry and academia,” said AnPac Bio CEO and Chairman Dr. Chris Yu.
To view the full article, visit https://ibn.fm/OLAqG
About AnPac Bio-Medical Science Co. Ltd.
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With one CLIA- and CAP-registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost & Sullivan’s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit www.AnpacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php